Cell line · CVCL_1738
Papers47
1 more article gives this line's RRID in its Methods without naming the line nearby, so it is not listed.
1 to 20 of 47
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Reprogramming-driven Proteomic Shifts Mirror Bladder Cancer Progression and Reveal Biomarker Candidates Across Disease Grades. | Cancer Genomics Proteomics | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Conjoining cell reprogramming and mass spectrometry to identify the proteomic variations in the reprogrammed bladder cancer cells: finding cues of normalisation. | BMC Cancer | 2026 | Its Methods give the RRID and name the line | PubMed | |
| HOXB4 Promotes Bladder Cancer Progression in Part Through Transcriptional Activation of Smoothened. | FASEB J | 2026 | Its Methods give the RRID and name the line | PubMed | |
| piR-43452 suppresses bladder cancer progression and enhances gemcitabine sensitivity via GTSF1/PIWIL4-mediated LRP1 mRNA destabilization. | Transl Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Glycosylated LGALS3BP is highly secreted by bladder cancer cells and represents a novel urinary disease biomarker. | Mol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Long Noncoding RNA DGUOK-AS1 Promotes Bladder Cancer Progression by Enhancing EFTUD2 Stability. | Cancer Res Treat | 2026 | Its Methods give the RRID and name the line | PubMed | |
| PIN1 Prolyl Isomerase Promotes Initiation and Progression of Bladder Cancer through the SREBP2-Mediated Cholesterol Biosynthesis Pathway. | Cancer Discov | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Enhancing immunotherapy through PD-L1 upregulation: the promising combination of anti-PD-L1 plus mTOR inhibitors. | Mol Oncol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| PD-L1 (CD274) promoter hypomethylation predicts immunotherapy response in metastatic urothelial carcinoma. | Oncoimmunology | 2023 | Its Methods give the RRID and name the line | PubMed | |
| STAG2 expression is associated with adverse survival outcomes and regulates cell phenotype in muscle-invasive bladder cancer. | Cancer Res Commun | 2022 | Its Methods give the RRID and name the line | PubMed | |
| Activation of cGAS-STING Signal to Inhibit the Proliferation of Bladder Cancer: The Immune Effect of Cisplatin. | Cells | 2022 | Its Methods give the RRID and name the line | PubMed | |
| Pan-cancer proteomic map of 949 human cell lines. | Cancer Cell | 2022 | Cellosaurus cites it | PubMed | |
| FOXC1 Binds Enhancers and Promotes Cisplatin Resistance in Bladder Cancer. | Cancers (Basel) | 2022 | Its Methods give the RRID and name the line | PubMed | |
| Development of Novel Aptamer-Based Targeted Chemotherapy for Bladder Cancer. | Cancer Res | 2022 | Its Methods give the RRID and name the line | PubMed | |
| Immunosuppression Induced by Glutamine Deprivation Occurs via Activating PD-L1 Transcription in Bladder Cancer. | Front Mol Biosci | 2021 | Its Methods give the RRID and name the line | PubMed | |
| The Clinical Implications and Molecular Mechanism of CX3CL1 Expression in Urothelial Bladder Cancer. | Front Oncol | 2021 | Its Methods give the RRID and name the line | PubMed | |
| Human primed ILCPs support endothelial activation through NF-κB signaling. | Elife | 2021 | Its Methods give the RRID and name the line | PubMed | |
| Quantitative Proteomics of the Cancer Cell Line Encyclopedia. | Cell | 2020 | Cellosaurus cites it | PubMed | |
| Next-generation characterization of the Cancer Cell Line Encyclopedia. | Nature | 2019 | Cellosaurus cites it | PubMed | |
| Epigenetic regulation of mammalian Hedgehog signaling to the stroma determines the molecular subtype of bladder cancer. | Elife | 2019 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_1738/papers